You are viewing the site in preview mode

Skip to main content

Table 2 Main clinical outcomes of the project at 4 weeks after treatment change

From: Safely reducing haemodialysis frequency during the COVID-19 pandemic

  Twice weekly HD Thrice weekly HD P value
URR (%)a 72.6 [66.4–77.2] 69.7 [62.7–74.8] 0.009
Corrected Calciumb (mmol/L) 2.33 [2.20–2.42] 2.33 [2.22–2.43] 0.921
Phosphatec (mmol/L) 1.77 [1.44] 1.65 [1.33–2.09] 0.117
Potassiumd (mmol/L) 4.80 [4.30–5.40] 4.90 [4.40–5.40] 0.329
UF per session (L) 1.50 [1.00–2.03] 2.00 [1.40–2.63] < 0.001
COVID-19 positive (%) 9 (5.4) 20 (8.5) 0.245
Hospitalisations (%) 13 (7.8) 17 (7.2) 0.813
Deaths (%) 6 (3.6) 6 (2.5) 0.535
  1. Results are expressed as median [IQR; interquartile range] or n (%). p-value calculated using Mann-Whitney U Test. Categorical variables were analysed by Chi-square test. Hospitalisation data includes patients who were hospitalised for COVID-19 and prior to death. amissing for 56 patients in twice weekly group and 126 patients in thrice weekly group. bmissing for 9 patients in twice weekly group and 46 patients in thrice weekly group. cmissing for 9 patients in twice weekly group and 46 patients in thrice weekly group. dmissing for 32 patients in thrice weekly group
  2. COVID-19, hospitalisations and deaths % calculated in relation to original number of patients n = 166 / n = 236. Abbreviations: URR Urea reduction ratio, UF Ultrafiltration